Latest news with #NSAA
Forbes
3 days ago
- Business
- Forbes
U.S. Ski Resorts Had Second-Best Season On Record In 2024–25
As the ski industry faces issues ranging from corporate consolidation to increasingly unpredictable snowfall, there is some good news to end the 2024–25 season. According to preliminary data from the National Ski Areas Association (NSAA), U.S. ski areas saw the second-highest visitation on record this past season, with a total of 61.5 million skier visits. That marks a a 1.7% increase over the previous season. And the number of skier visits for the 2024–25 season will continue to climb as several resorts have extended their seasons. The highest visitation totals on record, 65.4 million in the 2022–23 season, were the result of a post-Covid surge, but this number is considered an outlier across the travel and recreation industries. The visitation total is one data point in an overall positive trend for the industry. Globally, ski resorts saw more than 366 million skier visits last season. The average for worldwide skier visits is higher after Covid-19 than in the years before 2020, per the International Report on Snow & Mountain Tourism. In 2023–24, Italy and Chile marked their best-ever ski seasons. Domestically, the NSAA set a goal several years ago of reaching a three-year rolling average of 60 million skier visits at U.S. resorts. The industry has surpassed that figure for four consecutive seasons. The number of ski areas operating in the U.S. also rose from 484 last season to 492 this season. The NSAA groups U.S. ski resorts into six regions: the Pacific Northwest, Pacific Southwest, Rocky Mountain, Midwest, Northeast and Southeast. In particular, small- and medium-sized ski areas saw increased visits, and the Pacific Northwest enjoyed a a record-setting year, with 4.7 million skier visits, a 10.9% increase over the previous year. After a decline in visits in 2023–24 due to unseasonably warm weather, the Midwest enjoyed a 21.8% increase in skier visits in 2024–25. Visits in the Rocky Mountain region, which accounted for 42.9% of all national visits in 2024-25, were the third-most out of 47 recorded seasons. While snowfall averages were down slightly (6.9% year-over-year) in the Rocky Mountain, Pacific Southwest and Pacific Northwest regions, the Southeast and Midwest regions saw above-average snow totals. The Northeast met its average. 'While weather will always be unpredictable, this year was less volatile overall, and nearly every region saw solid snowfall,' said NSAA president and CEO Michael Reitzell. Capital investment by U.S. ski areas (based on reported investment from 135 responding areas) totaled $624.4 million, the majority of which went to lift infrastructure. Nationwide, 97 new and upgraded lifts were installed. Surveyed ski areas reported plans for 47 new lifts and 70 lift upgrades in 2025–26. Season pass holders made up nearly half (49%) of all visits nationally this season, with 32% of visits coming from day lift tickets. The remaining visits are composed of factors such as frequency products, off-duty employees and complimentary products. 'The 2024–25 season may come to represent a new baseline for the industry. Even if 'normal' continues to evolve, this season gives us a strong point of reference for what steady, healthy growth looks like,' Reitzell added.
Yahoo
26-05-2025
- Climate
- Yahoo
Rocky Mountain region sees 3rd best ski season; US industry reports 2nd best season
DENVER (KDVR) — This year's ski season was good — really good, according to the National Ski Areas Association, which said about 61.5 million skiers visited U.S. areas this winter. That means the 2024-25 ski season had the second-most visits on record to U.S. ski areas. The 2022-23 season remains the most attended in recorded history, with just under 65.4 million skier visits recorded in the U.S. The association noted that this number is 'widely considered an anomaly across the travel and recreation industries,' spurred by a post-COVID-19 surge. FOX31 Weather: View the latest Denver forecasts, maps and radar The NSAA counts skier visits as each time a lift ticket or pass is used at a ski area, and the currently released numbers are preliminary, as several ski areas extended their seasons after the release was published on May 12. That includes Arapahoe Basin, which has set its closing day for June 8. However, the association found that this previous ski season had 1.7% more visits than the previous season. 'Several years ago, we set an ambitious goal of reaching a three-year rolling average of 60 million skier visits. We've now surpassed that benchmark for four consecutive seasons,' said NSAA President and CEO Michael Reitzell in the group's announcement of the visit numbers. 'While weather will always be unpredictable, this year was less volatile overall, and nearly every region saw solid snowfall.' The group noted that more ski areas were operating this year, up to 492 from 484. 'The 2024-25 season may come to represent a new baseline for the industry. Even if 'normal' continues to evolve, this season gives us a strong point of reference for what steady, healthy growth looks like,' Reitzell added in the announcement.' NSAA said that the Rocky Mountain region, which includes New Mexico, Colorado, Utah, Wyoming, Idaho and Montana, accounted for nearly 43% of all ski visits nationwide during the 2024-25 ski season, and ranked third out of the 47 seasons on record. However, the Pacific Northwest recorded its best season on record: 4.7 million visits, which represents a 10.9% increase over the 2023-24 season. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
23-05-2025
- Business
- Yahoo
Astellas Pharma and Pfizer's Xtandi shows long-term survival in prostate cancer
Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year follow up of overall survival, or OS, benefits and a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer treated with Xtandi – enzalutamide -, an androgen receptor pathway inhibitor, plus androgen deprivation therapy vs. placebo plus ADT. These data will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago. In patients with high-volume disease a 36-month improvement in median OS was observed. Additional clinically relevant subgroups of patients were evaluated, showing consistently improved survival: low-volume disease; patients who had previously received docetaxel therapy and those who had not received prior docetaxel therapy. The incidence of treatment-emergent adverse events in the five-year follow-up is consistent with prior ARCHES analyses and no new safety signals were identified. These results of the five-year follow-up from the ARCHES study will be submitted for publication in a peer-reviewed journal in the near future. The median OS in the XTANDI group was 8.0 years and 5.8 years in the NSAA group. OS at 96 months was 50% with Xtandi and 40% for NSAA; progression-free survival also favored Xtandi over NSAA. Mean duration of treatment was longer for Xtandi than NSAA, with 33% remaining on Xtandi and 88% of these patients remained at the full dose of 160 mg. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on PFE: Disclaimer & DisclosureReport an Issue Trump Trade: White House announces 'Golden Dome' missile-defense shield Class Action Lawsuit Against Cerevel Therapeutics Holdings, Inc. Pfizer's Strategic Oncology Moves: Balancing Promise and Risk Pfizer's Strategic Focus and Market Challenges Justify Hold Rating Amid Uncertainties HHS says 'taking immediate steps to implement' Trump drug pricing order
Business Insider
23-05-2025
- Business
- Business Insider
Astellas Pharma and Pfizer's Xtandi shows long-term survival in prostate cancer
Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year follow up of overall survival, or OS, benefits and a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer treated with Xtandi – enzalutamide -, an androgen receptor pathway inhibitor, plus androgen deprivation therapy vs. placebo plus ADT. These data will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago. In patients with high-volume disease a 36-month improvement in median OS was observed. Additional clinically relevant subgroups of patients were evaluated, showing consistently improved survival: low-volume disease; patients who had previously received docetaxel therapy and those who had not received prior docetaxel therapy. The incidence of treatment-emergent adverse events in the five-year follow-up is consistent with prior ARCHES analyses and no new safety signals were identified. These results of the five-year follow-up from the ARCHES study will be submitted for publication in a peer-reviewed journal in the near future. The median OS in the XTANDI group was 8.0 years and 5.8 years in the NSAA group. OS at 96 months was 50% with Xtandi and 40% for NSAA; progression-free survival also favored Xtandi over NSAA. Mean duration of treatment was longer for Xtandi than NSAA, with 33% remaining on Xtandi and 88% of these patients remained at the full dose of 160 mg. Confident Investing Starts Here:
Business Wire
19-05-2025
- Health
- Business Wire
Genethon Presents Two Year Consolidated Results of Its Gene Therapy Trial for Duchenne Muscular Dystrophy: Maintenance of Motor Functions and Significant, Sustained Reduction in CPK Levels in Patients Treated at the Effective Dose at ASGCT 2025
PARIS--(BUSINESS WIRE)-- Genethon unveiled the 2-year follow-up data from its GNT0004 gene therapy clinical trial for Duchenne Muscular Dystrophy (GNT-016-MDYF) at the annual meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans, May 13 – 17, 2025. Five patients, aged 6 to 10 years, were treated, 2 at the first dose level and 3 at the second dose level (3x10¹³ vg/kg). The initial part of the clinical trial aimed at selecting the optimal dose (dose escalation phase), evaluating the tolerance and preliminary efficacy of the treatment and determined the effective dose for the pivotal phase of the GNT-016-MDYF trial, which is expected to start in mid-2025 (3x10¹³ vg/kg). Genethon CEO Frederic Revah observed, "The results of our gene therapy GNT0004 are very positive in patients treated at the dose of 3x10¹³ vg/kg, both in terms of microdystrophin expression and clinical efficacy criteria. Besides these results, the advantage of our product lies in the selected dose for the pivotal phase, which is lower than those used in other gene therapy trials for Duchenne Muscular Dystrophy. We are currently preparing the pivotal phase that we will conduct in Europe and the US." Safety, efficacy, and pharmacodynamic results show good tolerance of GNT0004 associated with transient immunological prophylactic treatment, as well as efficacy data in terms of microdystrophin expression, CPK reduction, and clinical criteria (NSAA, timed tests). Patients treated at the effective dose show prolonged improvement or stabilization of motor functions and significant persistent reduction in creatine kinase (CPK) levels, a key marker of muscle damage. One-year post-treatment, the comparison of the three patients treated at the effective dose with a group of 34 untreated patients, matched by age and followed in the same centers and by the same practitioners, shows a difference of +4.7 points in the score obtained using the internationally recognized clinical evaluation scale NSAA between treated and untreated patients. At 24 months post-treatment, key observations include: For the 2 patients who reached 2 years post-treatment out of the 3 treated at the effective dose, the trial shows stabilization of motor functions measured by the NSAA scale , while untreated patients from the parallel natural history study showed a continuous and significant average decline in NSAA. For one treated patient, the observed improvement allowed reaching the maximum score of 34 at 12 months, confirmed at 24 months post-treatment. Stabilization of CPK reduction between 50% and 87% on average: >75% at 18 months post-treatment (data from the 3 patients treated at the effective dose), and persistent (up to 24 months follow-up for the first two patients treated at this dose). The reassuring safety profile of the gene therapy drug is confirmed two years after injection, without the occurrence of serious adverse effects at the selected dose, which is notably lower than that used for other gene therapy products under development for Duchenne Muscular Dystrophy. About GNT0004 and the trial The GNT0004 gene therapy is composed of an AAV8 (adeno-associated virus) vector and the optimized hMD1 transgene, a shortened but functional version of the gene encoding dystrophin, the protein deficient in people with DMD. This vector is designed to be expressed in muscle tissue and also in the heart, thanks to a tissue-specific Spc5-12 promoter sequence. GNT0004 is administered by a single intravenous injection. It was developed by Genethon, in partnership with the teams of Prof. Dickson (University of London, Royal Holloway) and the Institut de Myologie (Paris). The trial, sponsored by Genethon, combines Phases 1/2/3, a dose-escalation phase followed by a pivotal phase at the dose finally chosen. The trial is being carried out in France and the UK and includes boys aged 6 to 10 with DMD who have retained their ability to walk. About Duchenne muscular dystrophy DMD is a rare, progressive genetic disease affecting all the body's muscles, and mainly boys (1 in 5000). It is due to abnormalities in the gene responsible for producing dystrophin, a structural protein essential for the stability of muscle fiber membranes and their metabolism. The absence of dystrophin leads to progressive degeneration of skeletal and cardiac muscles, loss of walking and respiratory capacity, cardiomyopathy and death between the ages of 20 and 40. About Genethon A pioneer in the discovery and development of gene therapies for rare diseases, Genethon is a nonprofit organization created by the AFM-Téléthon. The first gene therapy to treat spinal muscular atrophy, incorporating technologies developed at Genethon, is marketed worldwide. With over 240 scientists and professionals, Genethon pursues its goal of developing innovative therapies that change the lives of patients suffering from rare genetic diseases. Thirteen products from Genethon's R&D or collaborations are in clinical trials for diseases of the liver, blood, immune system, muscles and eyes. A further seven products could enter clinical trials in the next five years. To find out more visit:
